Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Erdafitinib (JNJ-42756493) is a quinoxaline derivative compound, acts on FGFR1/2/3/4.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 9,000 | |||
10 mg | 在庫あり | ¥ 15,000 | |||
25 mg | 在庫あり | ¥ 22,500 | |||
50 mg | 在庫あり | ¥ 35,500 | |||
100 mg | 在庫あり | ¥ 55,000 | |||
500 mg | 在庫あり | ¥ 135,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 10,000 |
説明 | Erdafitinib (JNJ-42756493) is a quinoxaline derivative compound, acts on FGFR1/2/3/4. |
ターゲット&IC50 | FGFR4:5.7 nM, FGFR3:3.0nM, FGFR1:1.2 nM, FGFR2:2.5nM |
In vitro | JNJ-42756493 is a potent, oral pan-FGFR tyrosine kinase inhibitor with half-maximal inhibitory concentration values in the low nanomolar range for all members of the FGFR family (FGFR1 to FGFR4), with minimal activity on vascular endothelial growth factor receptor (VEGFR) kinases compared with FGFR kinases (approximately 20-fold potency difference). In vitro, the proliferation of cells treated with JNJ-42756493 is decreased, associated with increased apoptotic death and decreased cell survival[2]. |
In vivo | In vivo, growth of NCI-H716 tumors is delayed by 5 days by drug treatment alone, although when drug delivery is stopped the relative tumor volume increased compared to control[2]. JNJ-42756493 shows favorable drug like properties and displays a high distribution to lung, liver and kidney tissue. JNJ-42756493 is well tolerated at efficacious doses and results in potent dose-dependent antitumor activity accompanied by pharmacodynamic modulation of tumor FGFR and downstream pathway components[1]. |
細胞研究 | The effect of varying drug concentrations on cell growth and survival is evaluated at 72 h using sulforhodamine B (SRB) assay for the adherent cells (HCT116, HCA7, Caco2) and trypan blue dye exclusion for the suspension cells, NCI-H716. (Only for Reference) |
別名 | JNJ-42756493 |
分子量 | 446.54 |
分子式 | C25H30N6O2 |
CAS No. | 1346242-81-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 15 mg/mL(33.6 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 5.63 mg/mL (12.6 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Erdafitinib 1346242-81-6 Angiogenesis Apoptosis Tyrosine Kinase/Adaptors FGFR inhibit Fibroblast growth factor receptor JNJ42756493 Inhibitor JNJ-42756493 JNJ 42756493 inhibitor